Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.17 USD | +3.54% | -6.40% | -34.27% |
May. 10 | Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
May. 10 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 52.7M | Sales 2025 * | 101M | Capitalization | 85.78M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | 54 | EV / Sales 2024 * | 1.63 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.85 x |
P/E ratio 2024 * |
9.75
x | P/E ratio 2025 * |
1.86
x | Employees | 208 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.27% |
Latest transcript on Protalix BioTherapeutics, Inc.
1 day | +3.54% | ||
1 week | -6.40% | ||
Current month | +2.63% | ||
1 month | +2.63% | ||
3 months | -20.41% | ||
6 months | -15.83% | ||
Current year | -34.27% |
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 19-06-29 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 19-07-21 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 20-07-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 19-11-30 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 19-11-30 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 14-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 1.17 | +3.54% | 308,797 |
24-05-15 | 1.13 | -2.59% | 327,020 |
24-05-14 | 1.16 | +1.75% | 296,080 |
24-05-13 | 1.14 | +3.64% | 392,268 |
24-05-10 | 1.1 | -12.00% | 2,178,207 |
Delayed Quote Nyse, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.27% | 85.78M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.11% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- PLX Stock